Study: Moderna coronavirus vaccine appears safe, shows signs of working in older adults

News

FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder/File Photo

CHICAGO (NewsNation Now) — Results from an early safety study of Moderna coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said on Tuesday.

The study, published in the New England Journal of Medicine, offers a more complete picture of the vaccine’s safety in older adults, a group at increased risk of severe complications from COVID-19.

The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the study’s lead researchers from Emory University in Atlanta, said in a phone interview with Reuters.

The study was an extension of Moderna’s Phase I safety trial, first conducted in individuals aged 18-55. It tested two doses of Moderna’s vaccine – 25 micrograms and 100 micrograms – in 40 adults aged 56 to 70 and 71 and older.

Overall, the team found that in older adults who received two injections of the 100 microgram dose 28 days apart, the vaccine produced immune responses roughly in line with those seen in younger adults.

Moderna is already testing the higher dose in a large Phase III trial, the final stage before seeking emergency authorization or approval.

Side effects, which included headache, fatigue, body aches, chills and injection site pain, were deemed mainly mild to moderate.

In at least two cases, however, volunteers had severe reactions.

One developed a grade three fever, which is classified as 102.2 degrees Fahrenheit or above, after receiving the lower vaccine dose. Another developed fatigue so severe it temporarily prevented daily activities, Anderson said.

Typically, side effects occurred soon after receiving the vaccine and resolved quickly, he said.

Page 6 of NEJM Moderna COVID-19 Vaccine study
Contributed to DocumentCloud by Michael Geheren (NewsNation) • View document or read text
Atlanta resident Norman Hulme, 65, prepares to have his blood drawn as part of a Phase 1 clinical trial for a coronavirus disease (COVID-19) vaccine mRNA-1273 at Emory University’s Hope Clinic in Atlanta, Georgia, U.S. May 4, 2020. Picture taken May 4, 2020. Courtesy of Emory University/Handout via REUTERS.

“This is similar to what a lot of older adults are going to experience with the high dose influenza vaccine,” Anderson said. “They might feel off or have a fever.”

Norman Hulme, a 65-year-old senior multimedia developer at Emory who took the lower dose of the vaccine, said he felt compelled to take part in the trial after watching first responders in New York and Washington State fight the virus.

“I really had no side effects at all,” said Hulme, who grew up in the New York area.

Hulme said he was aware Moderna’s vaccine employed a new technology, and that there might be a risk in taking it, but said, “somebody had to do it.”

For transparency, NewsNation looked into the funding of the study:

“Moderna provided mRNA-1273 for use in this trial but did not provide any financial support. Employees of Moderna collaborated on the development of the protocol, contributed to the Investigational New Drug application, and participated in weekly team meetings regarding the study.”

New England Journal of Medicine

Latest News

More News

National News

More National

Washington D.C.

More Washington DC

Your Local Election HQ

More Your Local Election HQ
graphic of the Red Cross

Latest News

More News

Popular

KFOR Podcasts

More Podcasts

Follow @KFOR on Twitter